A Presentation on ICU Medical

Presented by Debajit Ghosh

Background

• Type : Public (NASDAQ: ICUI)

• Founded : 1984

• Headquarters : San Clemente, California, United States

• Key people : George "Doc" Lopez, MD, Founder and Chairman Steven C. Riggs, Acting President and CEO

• Products : disposable infusion therapy connectors and systems, critical care monitoring products and systems, oncology drug delivery systems

• Revenue : $316 million (2012)

Values

• We connect patients and caregivers through safe, life-saving, life-enhancing, medical devices.

• We connect innovation with empathy, empathy with technology, and technology with care.

• We connect answers to questions, outcomes to insights, and solutions to problems.

• We connect delivery and promise, care and cure.

• We connect people to hope.

History

• The company was founded in 1984 by George "Doc" Lopez, MD who developed a product known as the Click Lock to better secure IV lines after he lost a patient due to an accidental disconnect.

• In 2006, ICU Medical introduced its first products into the oncology marketplace. The Chemo Clave system from ICU Medical is a closed system transfer device (CSTD) that allows pharmacists and nurses to safely mix and administer hazardous drugs used to treat cancer patients without exposing themselves to these drugs.

Acquisition

• ICU Medical acquired the former Abbott Laboratories Critical Care business from Hospira in 2009.

• The acquisition allowed ICU to obtain new manufacturing space in Salt Lake City, Utah.

Products

• Infusion Therapy

ICU Medical provides a line of needle free IV connectors including the Neutron Catheter Patency Device (above) as well as a line of custom and stock IV sets.

Products

• Oncology The Diana Hazardous Drug Compounding System is the latest advance from ICU Medical for the safe handling of hazardous drugs used to treat many forms of cancer.

Products

• Critical CareThe Safe Set Closed Blood Sampling System from ICU Medical helps clinicians conserve blood in the operating room and intensive care unit.

Market Segment Overview

Growth Strategy• Continue mass customization in all our

market• Add more direct sales people to capitalize

on critical care acquisition, relationship with GPO’s and other market opportunities.

• Develop and launch new products while attacking open markets with proprietary products.

• Leverage distribution channels.• Pursue accretive alliances and acquisitions• New market opportunities from infection

control and safe handling of hazardous drug awareness regulation

Snapshot

Thank You